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The global prevalence of dementia has been estimated to be as high as 24 million, and is pre-
dicted to double every 20 years until at least 2040. As the population worldwide continues to
age, the number of individuals at risk will also increase, particularly among the very old.
Alzheimer disease is the leading cause of dementia beginning with impaired memory. The
neuropathological hallmarks of Alzheimer disease include diffuse and neuritic extracellular
amyloid plaques in brain that are frequently surrounded by dystrophic neurites and intra-
neuronal neurofibrillary tangles. The etiology of Alzheimer disease remains unclear, but it
is likely to be the result of both genetic and environmental factors. In this review we
discuss the prevalence and incidence rates, the established environmental risk factors, and
the protective factors, and briefly review genetic variants predisposing to disease.
Alzheimer disease is characterized by pro-gressive cognitive decline usually beginning
with impairment in the ability to form recent
memories, but inevitably affecting all intellec-
tual functions and leading to complete depen-
dence for basic functions of daily life, and
premature death. The pathological manifesta-
tions of Alzheimer disease include diffuse and
neuritic extracellular amyloid plaques and
intracellular neurofibrillary tangles accompa-
nied by reactive microgliosis, dystrophic neu-
rites, and loss of neurons and synapses (see
Serrano-Pozo et al. 2011). While these patho-
logical lesions do not fully explain the clinical
features of the disease, it has been hypothesized
that alterations in the production and process-
ing of amyloid b-protein may be the principal
initiating factor. The underlying causes of
these multifaceted changes remain unknown,
but advancing age, and genetic and nongenetic
antecedent factors are thought to play impor-
tant roles. Alzheimer disease is the most fre-
quent cause of dementia in Western societies.
In the US, approximately 5.5 million people
are affected, and the prevalence worldwide is
estimated to be as high as 24 million. Given
that both established and developing nations
are rapidly aging, the frequency is expected to
double every 20 years until 2040. The magni-
tude of the impending rise owing to societal
aging is considerable and will be a costly public
health burden in the years to come.
DEFINITIONS AND CRITERIA
In 1984, representatives from the National
Institute of Neurological and Communicative
Disorders and Stroke and the AlzheimerDisease
and Related Disorders Association (NINCDS-
ADRDA) developed a uniform set of criteria
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to enable clinicians and researchers to maintain
consistency in the diagnosis. They included
aspects of medical history, clinical examina-
tion, neuropsychological testing, and laboratory
assessments (McKhann et al. 1984). These crite-
ria have been remarkably reliable and valid for
the diagnosis of AD over the past three decades
(Galasko et al. 1994; Lim et al. 1999). The crite-
ria were developed with the intent of accurately
associating the clinical symptoms with the
neuropathological manifestations after death.
Levels of certainty were established that were
labeled as definite for autopsy-confirmed dis-
ease, probable for the typical clinical syndrome
without intervening issues and possible for diag-
noses complicated by disorders that might con-
tribute to the dementia. The criteria facilitated
estimates of the prevalence and incidence rates
of clinically diagnosed probable and possible AD.
The NINCDS-ADRDA criteria have very
recently been updated (McKhann et al. 2011).
With major advances in neuropsychological
assessment, brain imaging and the neuropatho-
logical, biochemical and genetic understanding
of this disease, revisions were considered a
necessity. The breadth of the AD phenotype in
society is greater than was previously thought.
For example, neuropathological changes may
precede clinical dementia by a decade or more.
The growing use of brain imaging and cerebro-
spinal fluid biomarkers (see below) may yield
both higher specificity and sensitivity in the
diagnosis and thus are considered in the up-
dated diagnostic criteria, especially when used
for clinical research. It has become increasingly
clear that cerebrovascular disease can coexist
with AD to a greatly varying extent, further
contributing to the cognitive and physical
dysfunction.
A set of newly proposed criteria are similar
to, but distinct from, those in the 1984
NINCDS-ADRDA criteria, with updates that
include the recognition of both amnestic and
nonamnestic symptom onset and alterations
in numerous other cognitive domains. Further,
cerebrovascular disease is now recognized as a
contributor to dementia, defined by a history
of a stroke temporally related to the onset
or worsening of cognitive impairment, the
presence of multiple or extensive infarcts, or
severe burden of hyperintense white matter
lesions by MRI. Accordingly, the presence of
substantial cerebrovascular pathology reduces
the certainty of a clinical diagnosis of AD to
possible. Hallucinations, delusions, Parkinson-
like motor manifestations and realted findings
can suggest dementiawith Lewy bodies or other
forms of dementia (see Tarawneh and Holtz-
man 2011; Weintraub et al. 2011).
In this chapter, we will discuss the preva-
lence and incidence rates of AD disease in devel-
oped and developing countries and summarize
the evidence for numerous antecedent risk fac-
tors, protective factors and genetic risk factors.
FREQUENCY OF ALZHEIMER DISEASE
In 2005, Alzheimer Disease International com-
missioned an international group of experts to
reach a consensus on dementia prevalence and
estimated incidence in 14 World Health Organ-
ization regions, based on epidemiological data
acquired over recent years. The results suggested
that 24.2 million people lived with dementia at
that time, with 4.6 million new cases arising
every year (Ferri et al. 2005). North America
and Western Europe have at age 60 the highest
prevalence of dementia (6.4 and 5.4% of the
population at age 60), followed by Latin Amer-
ica (4.9%) and China and its developing
western-Pacific neighbors (4.0%). The annual
incidence rates (per 1000) for these countries
were estimated at 10.5 for North America, 8.8
for Western Europe, 9.2 for Latin America and
8.0 for China and its developing western-Pacific
neighbors, increasing exponentially with age in
all countries, especially through the seventh and
eighth decades of life.
The prevalence rates for AD also rise expo-
nentially with age, increasing markedly after
65 years. There is almost a 15-fold increase in
the prevalence of dementia, predominately Alz-
heimer disease, between the ages of 60 and 85
years (Evans et al. 1989). Compared with Africa,
Asia and Europe, the prevalence of AD appears
to be much higher in the US, which may relate
to methods of ascertainment. The prevalence
may be higher among African-American and
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Hispanic populations living in the US, but
lower for Africans in their homelands, for rea-
sons that remain uncertain (Ogunniyi et al.
2000; Hendrie et al. 2001).
In 1998, Brookmeyer et al. estimated the
age-specific incidence rates of AD based on
studies in Boston, Framingham, Rochester,
and Baltimore. These rates doubled every 5
years after the age of 60 and rose from about
0.17% per year at age 65 to 0.71, 1.0, and
2.92% per year, respectively, at 75, 80, and 85
(Brookmeyer et al. 1998). This observation is
consistent with the vast majority of studies
that have estimated the age-specific incidence
of AD by sex and by ethnic group (Fig. 1;
Bachman et al. 1993; Letenneur et al. 1994;
Brayne et al. 1995; Hebert et al. 1995; Aevarsson
and Skoog 1996; Fratiglioni et al. 1997; Ander-
sen et al. 1999; Copeland et al. 1999; Launer
et al. 1999; Ganguli et al. 2000; Kawas et al.
2000; Lobo et al. 2000; Chandra et al. 2001;
Hendrie et al. 2001; Tang et al. 2001; Di Carlo
et al. 2002; Edland et al. 2002; Knopman et al.
2002; Kukull et al. 2002; Fitzpatrick et al.
2004; Lopez-Pousa et al. 2004; Nitrini et al.
2004; Ravaglia et al. 2005a; Jellinger and Attems
2010).
Two factors contribute to the difficulty in
establishing accurate incidence rates of AD: (1)
determining the age at onset; and (2) defining
a disease-free population. Nonetheless, studies
illustrate the consistent increase in incidence
rates with age from approximately 0.5% per
year among individuals aged 65–70 to approxi-
mately 6–8% for individuals over age 85. The
rapid rise in the frequencyof ADwith advancing
age, combined with the relatively long dura-
tion of the illness, accounts in large part for
the high prevalence of the disease worldwide.
Improvement and standardization of diagnostic
methods have provided ameans to compare esti-
mates of the frequency of AD across various
populations.
ANTECEDENT RISK FACTORS THAT
INCREASE THE RISKOF ALZHEIMER
DISEASE
A large number of factors has been associated
with increased risk of AD, but among those,
cerebrovascular disease and it antecedents are
the most consistently reported (Table 1). A his-
tory of diabetes, hypertension, smoking, obesity,
and dyslipidemia have all been found to increase
risk. Interestingly cerebrovascular disease, in-
cluding large cortical infarcts, single strategically
placed infarcts, multiple small infarcts, cerebral
hemorrhage, cortical changes owing to hypoper-
fusion, white matter changes and vasculopathies,
are all antecedents to dementia in general (Barba
et al. 2000; de Koning et al. 2000; Desmond et al.
2000, 2002; Zhu et al. 2000; Henon et al. 2001;
Klimkowicz et al. 2002; Honig et al. 2003; Liebe-
trau et al. 2003; Ivan et al. 2004; Linden et al.
2004; Srikanth et al. 2004; Tang et al. 2004;
Zhou et al. 2004; de Koning et al. 2005; Kuller
et al. 2005; Gamaldo et al. 2006; Jin et al. 2006;
Simons et al. 2006; Srikanth et al. 2006; Yip













Figure 1. The annual incidence rate (per 100 person-years) for Alzheimer disease. This graph is an estimate of
the data collected in 24 published studies.
Epidemiology of Alzheimer Disease



















Spring Harbor Laboratory Press 
 at COLUMBIA UNIVERSITY on June 13, 2017 - Published by Coldhttp://perspectivesinmedicine.cshlp.org/Downloaded from 
Cerebrovascular Disease
While it is clear that cerebrovascular disease
may present withmanifestations resembling de-
mentia, purely vascular dementia is uncommon.
More often cerebrovascular disease co-exists
with AD, so that evidence of both vascular dis-
ease and prototypical AD manifestations is
present (Schneider and Bennett 2010). Pendle-
bury and Rothwell (2009) analyzed data from
several hospital- and population-based cohorts
(7511 patients) and estimated a frequency of
new-onset dementia to be approximately 7%
following afirst stroke. Interestingly, the twofold
increased risk of dementia after incident stroke
was independent of the level or the rate of
change of prestroke cognitive function, sug-
gesting that prestroke cognitive function is not
a major determinant of the effect of stroke on
the risk of poststroke dementia (Reitz et al.
2008). The proposed mechanisms by which
stroke could lead to cognitive impairment
include destruction of brain parenchyma with
atrophy (Fein et al. 2000; Jellinger 2002), dam-
age in strategic locations that leads to amnestic
syndromes, such as thalamic strokes, an increase
in Ab deposition and the combination of vas-
cular and Alzheimer-type pathology (Blennow
et al. 2006). As one possible mechanism for an
increase in Ab, there is evidence from rodent
models of ischemia and hypoxia owing to hy-
poperfusion that a resulting overexpression of
p25 and cdk5 increases levels of BACE1, which
in turn increases amyloid precursor protein
(APP) processing (Wen et al. 2007, 2008).
White matter hyperintensities are fre-
quently observed by MRI in patients with
dementia, but the mechanisms by which white
matter changes contribute to cognitive decline
are unclear. Moreover because hypertension,
diabetes and microvasuclar disease are each
associated with these changes, there is no clear
process to explain the effect on cognition or
their role in Alzheimer disease. Thalamic vascu-
lar disease can lead to lower performance on
cognitive tasks, particularly those associated
with frontal and temporal lobe function,
including memory storage and retrieval (Swartz
et al. 2008; Wright et al. 2008).
Hypertension
Cross-sectional and longitudinal studies impli-
cate blood pressure as a possible contributor to
late-life dementia. Observational studies of the
association between elevated blood pressure
during middle age and late-life cognitive im-
pairment suggest that mid-life hypertension
increases the risk of late-life dementia (Kilander
et al. 2000; Launer et al. 2000; Wu et al. 2003;
Yamada et al. 2003; Elias et al. 2004; Whitmer
et al. 2005b). When hypertension is assessed
in later life, the association is somewhat ambig-
uous, in that both high and abnormally low
Table 1. Factors that modify the risk of Alzheimer disease
Antecedent Direction Possible mechanisms
Cardiovascular disease Increased Parenchymal destruction
Strategic location
 Ab deposition
Smoking Increased Cerebrovascular effects
Oxidative stress
Hypertension Increased and decreased Microvascular disease
Type II diabetes Increased Cerebrovascular effect
Insulin and Ab compete for clearance
Obesity Increased Increased risk of type II diabetes inflammatory
Traumatic head injury Increased Ab and amyloid precursor protein deposition
Education Decreased Provides cognitive reserve
Leisure activity Decreased Improves lipid metabolism, mental stimulation
Mediterranean diet Decreased Antioxidant, anti-inflammatory
Physical activity Decreased Activates brain plasticity, promotes brain vascularization
R. Mayeux and Y. Stern
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blood pressure are associated with dementia
(Skoog et al. 1996; Knopman et al. 2001; Morris
et al. 2001; Ruitenberg et al. 2001; Tyas et al.
2001; Bohannon et al. 2002; Lindsay et al.
2002; Posner et al. 2002; Elias et al. 2003; Kuller
et al. 2003; Piguet et al. 2003; Qiu et al. 2003;
Reinprecht et al. 2003; Verghese et al. 2003a;
Hebert et al. 2004; Solfrizzi et al. 2004; Tervo
et al. 2004; Borenstein et al. 2005; Petitti et al.
2005; Waldstein et al. 2005). With Alzheimer
disease onset and progression, blood pressure
begins to decrease, possibly related to vessel
stiffening, weight loss, and changes in the auto-
nomic regulation of blood flow.Hypertension is
a treatable medical disorder, but clinical trials
of antihypertensive medications in AD patients
have been attempted with inconsistent results
(Forette et al. 2002; Lithell et al. 2003; Tzourio
et al. 2003; Peters et al. 2010).
Type II Diabetes
The presence of type II diabetes is associated
with a approximately twofold increased risk
of AD (risk ratios vary between 1.5 and 4.0;
Luchsinger et al. 2001; Peila et al. 2002; Farris
et al. 2003; Luchsinger et al. 2004a). It has
been suggested that diabetes directly affects
Ab accumulation in the brain because hyperin-
sulinemia, which accompanies type II diabetes,
disrupts brain Ab clearance by competing for
the insulin-degrading enzyme (Selkoe 2000;
Farris et al. 2003). Receptors for advanced gly-
cation end-products, which also play a role in
the pathogenesis of diabetes, are present in
cels associated with senile plaques and neuro-
fibrillary tangles have been shown to be one
example of a cell surface receptor for Ab. Excess
adipose tissue may also predispose to type II
diabetes by producing adipokines critical to
metabolism and cytokines important in inflam-
mation. Adiponectin, leptin, resistin, TNF-a
and IL-6 are also produced and correlate with
insulin resistance and hyperinsulinemia, which
in turn may directly or indirectly affect AD risk
(Trujillo and Scherer 2005; Yu and Ginsberg
2005). A meta-analysis of longitudinal studies
examining type II diabetes and other disorders
of glucose or insulin levels found a pooled effect
size for diabetes of 1.54 in increasing AD risk
(95% confidence interval, CI, 1.33–1.79; z ¼
5.7; p , .001; Profenno et al. 2009).
Reger et al. (2008) showed that the adminis-
tration of intranasal insulin improved cognitive
performance in the early phases of AD and in
patients with amnestic mild cognitive impair-
ment, as did a 6-month trial of the PPAR-g ago-
nist, rosiglitazone (Watson et al. 2005). Another
study (Risner et al. 2006) in patients with AD
lacking the APOE-14 allele showed significant
although small improvements in cognitive
and functional improvement in response to
rosiglitazone, whereas in a study by Sato et al.
(2009), treatment with 15–30 mg pioglitazone
daily for 6 months led to improvements in cog-
nitive function and regional cerebral blood flow
in the parietal lobe.
Body Weight
Several cross-sectional and case–control studies
found that low bodymass indexor being under-
weight were apparent risk factors for dementia
and age-related brain changes such as atrophy
(Faxen-Irving et al. 2005). In contrast several
prospective studies linked both low and high
body weight, weight loss and weight gain to
risk of AD (Nourhashemi et al. 2002, 2003; Gus-
tafson et al. 2003; Bagger et al. 2004; Brubacher
et al. 2004; Buchman et al. 2005; Goble 2005;
Jeong et al. 2005; Kivipelto et al. 2005; Razay
and Vreugdenhil 2005; Rosengren et al. 2005;
Stewart et al. 2005; Tabet 2005; Whitmer et al.
2005a; Waldstein and Katzel 2006; Arbus et al.
2008; Atti et al. 2008). The strongest effect was
in a meta-analysis associating obesity (assessed
by high body mass index) and the risk of AD
(odds ratio, OR, 1.59 95% CI 1.02–2.5; z ¼
2.0; p ¼ .042) (Profenno et al. 2009). The
mechanisms by which body weight alters dis-
ease risk are unknown, but may include effects
such as insulin resistance or the co-incidence
of type II diabetes.
Smoking
Case–control studies initially suggested that
smoking lowers the risk of Alzheimer disease,
but subsequent prospective studies showed an
Epidemiology of Alzheimer Disease
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increased risk or no association (Doll et al.
2000). Smoking may increase the risk of de-
mentia by augmentation of cholinergic me-
tabolism, that is, up-regulating cholinergic
nicotinic receptors in the brain (Whitehouse
et al. 1988). Cholinergic deficits, characterized
by reduced levels of acetylcholine, choline ace-
tyl transferase and/or nicotinic acetyl choline
receptors, are invariably found in AD brains.
However, nicotine itself increases acetylcholine
release, elevates the number of nicotinic recep-
tors, and improves attention and information
processing. These actions may be opposed by
elevated oxidative stress caused by smoking,
and oxidative stress has been implicated as a
putative AD mechanism (Rottkamp et al.
2000; Perry et al. 2002) through the generation
of free radicals and affecting inflammatory–
immune systems, which in turn can activate
phagocytes that generate further oxidative dam-
age (Traber et al. 2000).
Traumatic Brain Injury
Compared with those without a history of
trauma, individuals having suffered traumatic
brain injury have a higher risk of dementia,
particularly those who carry the APOE-14 allele
(Koponen et al. 2004). Ameta-analyses demon-
strated that the riskof dementia is higher among
men (but not women) with a history of trau-
matic brain injury (Fleminger et al. 2003). Post-
mortem and experimental studies do support a
link: After human brain injury, both Ab depo-
sition (Hartman et al. 2002; Iwata et al. 2002;
Stone et al. 2002) and intraneuronal tau pathol-
ogy are increased, even in younger patients
(Smith et al. 2003). In addition, CSF Ab levels
are elevated and APP is overproduced (Emmer-
ling et al. 2000; Franz et al. 2003).
PROTECTIVE FACTORS THAT REDUCE
RISK OF ALZHEIMER DISEASE
Cognitive Reserve
Individuals with intellectually enriched life-
styles, such as those with high educational
and/or occupational attainment, have a reduced
risk of expressing AD pathology clinically.
While several studies reported no association
between educational level and risk of AD (Hall
et al. 2000; Chandra et al. 2001), a lower risk
of dementia in general in subjects with higher
education has been reported by several others
worldwide (Evans et al. 1993, 1997; Letenneur
et al. 1994, 1999; Stern et al. 1994; White et al.
1994; Qiu et al. 2001).
There is also evidence for a role of education
in age-related cognitive decline, with several
studies of “normal aging” reporting slower
cognitive and functional decline in individuals
with higher educational attainment (Chodosh
et al. 2002). These studies suggest that the
same education-related factors that delay the
onset of AD-type dementia also allow individu-
als to cope more effectively with brain changes
encountered in normal aging. In an ethnically
diverse cohort of nondemented elders in
New York City, increased literacy was also asso-
ciated with slower decline in memory, executive
function, and language skills (Manly et al.
2005).
Numerous studies have also explored the
relationship between leisure activities and
incident dementia. Community activities and
gardening were also protective for incident
dementia in China (Zhang et al. 1999). Having
an extensive social network was protective for
the development of dementia (Fratiglioni et al.
2004), and engagement in mental, social, and
other productive activities was associated with
decreased risk of incident dementia (Wang
et al. 2002). Participation in a variety of leisure
activities characterized as intellectual (e.g.,
reading, playing games, going to classes) or
social engagements (e.g., visiting friends or rel-
atives) was assessed in another population study
of nondemented elderly in New York (Scarmeas
et al. 2001). During follow-up, subjects with
high leisure activity had 38% less risk of devel-
oping dementia. In another prospective study,
frequencyof participation in common cognitive
activities (i.e., reading a newspaper, magazine,
or book) was assessed at baseline for 801 elderly
Catholic nuns, priests and brothers without
dementia (Wilson et al. 2002a). Finally, in
another prospective cohort from New York,
R. Mayeux and Y. Stern
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participation in leisure activities, particularly
reading, playing board games or musical in-
struments, and dancing, was associated with a
reduced risk of incident dementia (Verghese
et al. 2003b). Increased participation in cogni-
tive activities was also associated with reduced
rates of memory decline in this study.
A meta-analysis examined cohort studies of
the effects of education, occupation, premorbid
IQ and mental activities on dementia risk
(Valenzuela and Sachdev 2005). A summary
analysis was based on an integrated total of
29,279 individuals from 22 studies. The median
follow-up was 7.1 years. The summary odds
ratio for incident dementia for individuals
with high brain reserve compared with
low brain reserve was 0.54 (95% CI 0.49–0.59,
p , 0.0001), that is, a decreased risk of 46%.
Eight out of 33 data sets showed no significant
effect, whereas 25 out of 33 demonstrated a sig-
nificant protective effect. The authors found a
significant negative association between inci-
dent dementia risk (based on differential educa-
tion) and the overall dementia rate for each
cohort (r ¼ 20.57, p ¼ 0.04), indicating that
in negative studies there was a lower overall
risk of incident dementia in the cohort.
In contrast to the studies above, in which
greater cognitive reserve was associated with
better outcomes, a series of studies of patients
with AD suggested that those with higher
reserve have poorer outcomes (Table 1). In pro-
spective studies of AD subjects matched for
clinical severity at baseline (Geerlings et al.
1999; Stern et al. 1999), patients with greater
education or occupational attainment died
sooner than those with less attainment. Simi-
larly, higher educational or occupational at-
tainment (Stern et al. 1999; Scarmeas et al.
2006a), increased engagement in leisure activ-
ities (Helzner et al. 2007), and greater lifetime
cognitive activity (Wilson et al. 2010) have
each been associated with more rapid cognitive
decline in patients with diagnosed AD. Al-
though at first these findings appear contra-
intuitive, they are consistent with the cognitive
reserve hypothesis. The hypothesis predicts
that, at any level of assessed clinical severity,
the underlying pathology of Alzheimer disease
is more advanced in patients with higher than
those with less cognitive reserve. This would
result in the clinical disease emerging when
pathology was more advanced, as suggested by
the incidence studies reviewed above. This dis-
parity in degree of pathology would be present
at more advanced clinical stages of the disease
as well. At some point the greater degree of
pathology in the high-reserve patients would
result in more rapid death. Higher educational
attainment and greater engagement in leisure
activities and lifetime cognitive activities have
also been associated with more rapid cognitive
decline in patients with Alzheimer disease.
Diet
Dietary fats can increase cholesterol levels,
which in turn can increase vascular risk in the
brain. This sequence may also increase the risk
of AD (Sparks et al. 2000). Intake of saturated
fats in the fifth (highest) quintile compared
with the first quintile of dietary fats was associ-
ated with a doubling of risk of incident Alz-
heimer disease. Trans-unsaturated fats were
associated with a 3-times-higher risk of devel-
oping AD, whereas the highest intake of n-6
polyunsaturated fats and monounsaturated
fat reduced AD risk (Morris et al. 2003). An
increased risk of AD has also been associated
with higher intake of total and saturated fat,
with no evidence of an associationwith polyun-
saturated fat (Luchsinger et al. 2002).
Omega-3 fatty acids stems are essential diet-
ary components in early brain development.
Many studies have found that consumption of
fish or omega-3 fatty acids is associated with a
reduced risk of AD (Morris et al. 2003; Schaefer
et al. 2006; van Gelder et al. 2007). For example,
a study in France found that weekly consump-
tion of fish was associated with reduced AD
risk, and regular consumption of omega-3
rich oils was associated with increased risk
of all causes of dementia (Barberger-Gateau et
al. 2007).
Two studies found a lower risk of Alzheimer
disease in individuals with a higher dietary
intake of vitamin D (Engelhart et al. 2002;
Morris et al. 2002). This association was not
Epidemiology of Alzheimer Disease
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noted in a third study, perhaps because the
level of vitamin D intake was lower (Luchsinger
et al. 2003).
Total homocysteine has also been inconsis-
tently associated with AD (Luchsinger et al.
2004b; Seshadri 2006; Reitz et al. 2009). Con-
centrations of homocysteine are largely deter-
mined by certain B vitamins. Based on folate
levels measured in serum, therewas preliminary
evidence from two studies that low folate levels
are associated with increased AD risk (Wang
et al. 2001; Ravaglia et al. 2005b). Some studies
that used estimated dietary intake of folate and
B vitamins based on self-reported information
reported conflicting results. One reported an
association between higher intake of folate
and reduced risk of AD (Luchsinger et al.
2007), whereas another did not find a signifi-
cant reduction in AD risk associated with folate
intake (Morris et al. 2006). Neither study found
an association between vitamins B6 or B12 and
risk of AD.
Inconsistencies in the existing literature
regarding some of the above dietary elements
and AD risk may be a result of failure to con-
sider possible additive and interactive (antago-
nistic or synergistic) effects among nutritional
components, which may be better captured in
a composite dietary pattern such as the Medi-
terranean diet. The latter is characterized by
high intake of vegetables, legumes, fruits, and
cereals; high intake of unsaturated fatty acids
(mostly in the form of olive oil), but low intake
of saturated fatty acids; amoderately high intake
of fish; a low-to-moderate intake of dairy prod-
ucts (mostly cheese or yogurt); a low intake of
meat and poultry; and regular but moderate
amounts of ethanol, primarily in the form of
wine and generally duringmeals (Trichopoulou
et al. 2003). In one study (Scarmeas et al.
2006b), higher adherence to the Mediterranean
diet was associated with lower risk of AD (haz-
ard ratio, 0.91; 95% CI, 0.83–0.98; p ¼ 0.015).
Compared with subjects in the lowest Mediter-
ranean diet tertile, subjects in the middle tertile
had an AD hazard ratio of 0.85 (95% CI, 0.63–
1.16) and those in the highest tertile had a
hazard ratio of 0.60 (95% CI, 0.42–0.87) (p for
trend ¼ 0.007). In a follow-up analysis, the
Mediterranean diet was also associated with a
reduced risk of developing mild cognitive
impairment and of progression from mild cog-
nitive impairment to AD (Scarmeas et al. 2009).
Physical Activity
Exercise can enhance learning in both young
and aged animals (van Praag et al. 1999),
activate brain plasticity mechanisms, remodel
neuronal circuitry in the brain (Cotman and
Berchtold 2002), promote brain vascularization
(Black et al. 1990), and stimulate neurogenesis
(van Praag et al. 1999). Itmay also increase neu-
ronal survival and resistance to brain insults
(Carro et al. 2001), increase levels of brain-
derived neurotrophic factor, mobilize gene
expression profiles that would be predicted to
benefit brain plasticity (Cotman and Berchtold
2002), and reduce levels of C-reactive protein
and interleukin-6, two inflammatory markers
(Ford 2002; Reuben et al. 2003). A Cochrane
review (Angevaren et al. 2008) found that eight
of 11 random, controlled trials of exercise in
older people without known cognitive impair-
ment reported that aerobic exercise interven-
tions were associated with improvements in
cognitive function.
Although some studies have failed to
detect an association between physical activity
and dementia (Wang et al. 2002; Wilson et al.
2002a; Verghese et al. 2003b), others have
observed a beneficial role (Podewils et al.
2005; Rovio et al. 2005; Larson et al. 2006;
Wang et al. 2006). A study of 1880 commu-
nity-dwelling elders without dementia living
in New York City investigated the combined
association of diet and physical activity with
Alzheimer risk. A combination of adherence
to a strict Mediterranean-type diet and regular
physical activity (compared with no orminimal
physical activity) was associated with a signifi-
cant reduction in risk of AD.
Cognitive Enhancement
Several studies have specifically examined the
potential effects of cognitive engagement on
the risk of AD (Wilson et al. 2002b, 2007;
R. Mayeux and Y. Stern
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Verghese et al. 2003b; Akbaraly et al. 2009).
The studies used self-report of the frequency
of involvement in specific activities that poten-
tially have a cognitive component. In the
Three-City cohort study, analyses were carried
out on 5698 dementia-free participants aged
65 and over. Stimulating leisure activities were
significantly associated with a reduced risk of
AD (hazard ratio (HR) ¼ 0.39). This finding
was independent of other proxies of cognitive
reserve and remained significant after adjusting




Rare mutations in three genes have been firmly
implicated in familial early-onset disease: APP,
PSEN1, and PSEN2 (Table 2; Goate et al. 1991;
Levy-Lahad et al. 1995a,b; Rogaev et al. 1995;
Sherrington et al. 1995, 1996). These mutations
have high penetrance, aremostly inherited in an
autosomal dominant pattern and lead with cer-
tainty to enhanced relative levels of the Ab42
peptide, its aggregation and an early onset of
disease, typically beginning in the fourth or fifth
decade of life. APP mutations account for
an even smaller fraction (less than 1% of all
AD patients). Rare variants such as these are
occasionally seen in families of patients with
familial Alzheimer disease having later onset
(Athan et al. 2001). All APP missense muta-
tions influence APP proteolytic processing
and/or aggregation, because they are positioned
in or near the Ab-coding exons (16 and 17) of
APP (see AD Mutation Database, http://www.
molgen.vib-ua.be/ADMutations/). The muta-
tion spectrum also includes microduplication
at the APP locus on Ch 21. At the time of writ-
ing, 182 different AD-related mutations in 401
families have been identified in PSEN1, whereas
only 14 mutations in 23 families were de-
tected in PSEN2 (http://www.molgen.vib-ua.
be/ADMutations/). Themajority of PSENmu-
tations are single-nucleotide substitutions,
but small deletions and insertions have also
been described. PSEN mutations alter the
g-secretase-mediated proteolytic cleavage of
APP, resulting in an increased Ab42/Ab40 ratio
by an increase in Ab42 and/or a decrease in
Ab40, suggesting a partial loss-of-function
mechanism rather than a gain-of-function in
PSEN (see Tanzi 2011 for a detailed review).
Although mutations in these three genes repre-
sent rare causes of AD, their discovery greatly
supported a pivotal role for Ab in the patho-
genesis of AD. According to this amyloid (or
Ab hypothesis), neurodegenerative processes
are the consequence of an imbalance between
Ab production and Ab clearance, suggesting
Table 2. Gene variants associated with Alzheimer disease
Gene Main alteration Presumed mechanism
Amyloid precursor protein (APP) Mutation Autosomal dominant, mostly early onset
Presenilin 1 (PSEN1) Mutation Autosomal dominant, mostly early onset
Presenilin 2 (PSEN2) Mutation Autosomal dominant, mostly early onset




Common variant Familial and sporadic, late onset




Common variant Sporadic, late onset
Complement component
(3b/4b) receptor 1 (CR1)
Common variant Sporadic, late onset
Bridging integrator 1 (BIN1) Common variant Sporadic, late onset
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that other genes involved in these pathways
might also turn out to be risk factors.
Common Variants
The strongest common genetic variant for typ-
ical late-onset AD beginning after age approxi-
mately 65 years is apolipoprotein E (APOE), a
three-allele polymorphism (12, 13, and 14)
where 13 is considered a neutral allele, 14 the
high-risk allele, and 12 a protective allele
(Table 2). The 14 allele influences age at onset
in a dose-dependent manner (Corder et al.
1993). However, more than half of the patients
with late-onset disease do not have the high-
risk 14 allele. The population attributable risk
related to APOE-14 has been estimated at 20%
(Slooter et al. 1998). Genome-wide association
(GWA) studies have identified variants in CLU,
PICALM, CR1, and BIN1 as putative suscepti-
bility loci (Harold et al. 2009; Lambert et al.
2009; Seshadri et al. 2010). These genetic
variants have been confirmed in other non-
Hispanic and Hispanic populations (Carras-
quillo et al. 2010; Jun et al. 2010; Lee et al.
2010). The odds ratios for these genes are
much lower than for APOE (OR ¼ are 3.2 and
14.9 for 13/14 and 14/14, respectively [Farrer
et al. 1997]) and range from 1.16 to 1.20 for
CR1, CLU, and PICALM.
Familial Late-Onset Alzheimer Disease
Bertram et al. (2008) performed aGWA study in
1376 samples from 410 families with late-onset
Alzheimer disease (LOAD) and subsequently
replicated their findings. A locus on chromo-
some 14q31 was strongly associated with
LOAD, but the identity of the underlying locus
is unknown and may be a modifier of onset
age. The results of GWA studies in the NIA-
LOAD Family Study, involving 900þ families
stratified by APOE genotype, also identified
single-nucleotide polymorphisms on chromo-
some 10p14 in CUGBP2 with genome wide sig-
nificance within individuals with one APOE 14
allele, which was replicated in an independent
CaribbeanHispaniccohort (Wijsmanetal.2011).
The NIA-LOAD Family Study also replicated
the variants in BIN1 and provided modest con-
firmation for CLU, but not for CR1 or PICALM
after APOE adjustment (Hollingworth et al.
2011; Naj et al. 2011). The role of these genes
in the pathogenesis of Alzheimer’s disease re-
mains to be determined, but it is clear that large
sample sizes have enabled identification of these
putative gene variants.
Finally, variants in SORL1, which encodes
a protein involved in trafficking of APP, are
associated with late-onset AD. Although in
line with other recently described genetic links
for AD (Lee et al. 2007; Rogaeva et al. 2007),
the effect sizes of the SORL1 associations are
modest (Reitz et al. 2011). Variants in the
SORL1 homolog, SORCS1, are also modestly
associated with AD. Overexpression of either
gene leads to a decrease in Ab levels in cultured
cells, whereas inhibition by RNAi increases
Ab. Thus, both genes may play a role in AD
pathogenesis.
Although these results of the published
GWA studies are informative, the genetic associ-
ations need functional validation. GWA studies
represent a method of screening the genome,
but limitations exist in their ability to detect
true associations. The results of such studies
might be difficult to replicate if the real effect
turns out to be smaller than the effect observed
in the initial study. In addition, GWA studies
may not detect associations with multiple rare
variants at a single site (which are better
detected by linkage studies) or with single rare
variants (minor allele frequency ,5%). Finally,
such studies alone cannot prove causality or
establish the biological significance of an
observed genetic association.
CONCLUSIONS
Our understanding of AD pathogenesis has
grown substantially over the past two decades.
However, with the large numbers of individuals
reaching the age of highest risk, some would say
that we have a long way to go toward preventing
or limiting the full impact of the disease. Cur-
rent treatments are palliative at best and newer
therapies remain unproven. Knowing who is
a risk and why will make prevention and
R. Mayeux and Y. Stern
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management easier in the future (Aisen et al.
2011; Lee et al. 2011; Schenk et al. 2011).
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